Posts for category: Recent News
Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the 8th Clinical Trials on Alzheimer’s Disease (CTAD). The conference will be held November 5-7 in…
BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at the Parc 55 San Francisco. CEO Jerry McLaughlin will present on Wednesday, October 21, at…
Public-private partnership will support first and only trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD, September 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of…
First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease Restored brain function to pre-disease levels and significantly improved memory BALTIMORE, MD March 11, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of…
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD January 28, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases, announced today that the Company has…
BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the Company will present at the 7th Annual Biotech Showcase 2015. Jerry McLaughlin, AgeneBio’s president and…
BALTIMORE, MARYLAND—AgeneBio, a pharmaceutical company developing innovative therapeutics that prevent neurodegeneration and preserve and restore brain function, today announced that the Company’s founder and chief scientific officer Michela Gallagher, PhD, has received the Society for Neuroscience’s Mika Salpeter Lifetime Achievement Award. For the past 35 years, Dr. Gallagher’s research at Johns Hopkins and the University…
BALTIMORE, MARYLAND—AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients’ cognitive function for a range of debilitating neurodegenerative diseases, today announced the appointment of Patrick LePore as chairman of the board and Jerry McLaughlin as president and chief executive officer. Both appointments are effective immediately. “Pat and Jerry are distinguished leaders…